Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Share transfer and ownership restructuring – related party transaction

FluoGuide
Download the release

FluoGuide A/S announces that two of its shareholders, both of whom hold management and/or board positions in the Company, have entered into an agreement regarding a reorganisation of their shareholdings in the Company. There is no change in the ultimate ownership to the shares.

Background

Morten Albrechtsen who serves as Chief Executive Officer and Andreas Kjær who serves as Board Member of FluoGuide A/S and Chief Scientific Officer have agreed to restructure their ownership of shares in FluoGuide A/S so that their combined shareholding forthwith will be held by a jointly owned company. Prior to the reorganization Morten Albrechtsen ultimately owns 10.9% of the shares in FluoGuide A/S (1,488,610 shares) and Andreas Kjær ultimately owns 15.6% of the shares in FluoGuide (2,126,107 shares).

Transaction Details

Morten Albrechtsen’s wholly owned company will transfer all of its shares in FluoGuide A/S to Life Science ApS which before the transaction is wholly owned by Andreas Kjær. In consideration for this transfer, Morten Albrechtsen will receive shares in Life Science ApS reflecting the number of shares held by each of them in FluoGuide A/S. Life Science ApS will following the transaction own in aggregate 26.5% of the shares in FluoGuide A/S (3,614,717 shares) prior to registration the directed share issuance recently announced by FluoGuide A/S. Following the capital increase Life Science ApS will own 22.1% shares in FluoGuide A/S.

Governance Arrangements

The shareholders have agreed that all decisions in Life Science ApS shall be made unanimously. Both parties have equal influence over decisions affecting their combined shareholding in the Company. In the event of disagreements each party can require that Life Science ApS is liquidated.

Ultimate Ownership and Control

The transaction will not result in any change to the ultimate beneficial ownership of the shares in FluoGuide A/S. The economic interests of both shareholders remain unchanged following the reorganisation. Both individuals will continue in their respective roles within FluoGuide A/S.

Related Party Considerations

Given the positions held by both shareholders within the Company, this transaction has been disclosed in accordance with applicable related party requirements. The transaction is a private arrangement between the shareholders and does not involve any Company assets or resources. The board has been informed of the arrangement and the chairman of the board of directors notes that it does not affect the Company's operations or governance.

Impact on the Company

The reorganisation is a matter between the two shareholders and does not affect the Company's operations, strategy, or financial position.

Certified Adviser:
Svensk Kapitalmarknadsgransking AB
Website: www.skmg.se

For further information, please contact:
Morten Albrechtsen, CEO
FluoGuide A/S
Phone: +45 24 25 62 66
E-mail: ma@fluoguide.com

This information is information that FluoGuide A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-11-03 21:30 CET.

About FluoGuide
FluoGuide lights up cancer to maximize surgical outcomes in oncology. FluoGuide’s lead product, FG001, is designed to improve surgical precision by lighting up cancer intraoperatively. The improved precision has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision enhances the likelihood of complete cure and lower healthcare costs. FluoGuide has demonstrated that FG001 is both effective and well tolerated several phase II clinical trials. The lead indications of FG001 are aggressive brain cancer (glioblastoma) and oral head and neck cancer. FluoGuide has entered partnerships with leading MedTech companies with the aim of accelerating development and commercialization. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.

For more information on FG001 or FluoGuide’s uPAR technology platform, please visit our home page www.fluoguide.com

Attachments
Share transfer and ownership restructuring – related party transaction

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.